sponsored
PatientsVille.com Logo

PatientsVille

Adverse Medical Research Studies

Up-to-date List of Adverse Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Adverse Medical Research Studies

Rank Status Study
1 Recruiting International Multicentre Prospective Study on Morphine-induced Adverse Drug Reactions in Emergency Departments: Description and Predictive Factors.
Condition: To Describe and to Analyze Factors Predicting Adverse Events in Patients Receiving Morphine for Acute Pain in an Emergency Setting.
Intervention:
Outcome Measures: Occurrence of morphine related Adverse-event;   Description of Adverse effects caused by morphine
2 Unknown  Enhancing the Detection and Management of Adverse Drug Events in Nursing Homes
Condition: Adverse Drug Event
Intervention: Behavioral: Active medication monitoring
Outcome Measures: Adverse drug event detection;   Adverse drug event response time
3 Unknown  Emergency Department Crowding in Relation to In-hospital Adverse Medical Events
Condition: Adverse Effects
Intervention:
Outcome Measures: Occurrence of six Adverse events;   Mortality;   ED length of stay;   Hospital length of stay;   Time to antibiotics administration in case of pneumonia
4 Recruiting Hospital Intensive Monitoring of Adverse Drug Reactions of Qingkailing Injection In The Next Two Years
Conditions: Adverse Drug Events;   Adverse Drug Reactions
Intervention: Drug: Qingkailing Injection
Outcome Measures: incidence of severe Adverse drug reactions;   incidence of Adverse drug reactions
5 Recruiting Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study
Conditions: HIV Infection;   Adverse Drug Reaction;   Quality of Life
Intervention: Drug: Raltegravir switch
Outcome Measures: The proportion of patient-reported clinical Adverse events;   The percent changes from baseline in plasma lipid profiles (total cholesterol, LDL Cholesterol, HDL Cholesterol, triglycerides);   The proportion of patients with treatment failure;   The proportion of patients who are free of "virological failure";   The change from baseline in CD4 cell counts;   the change from baseline in life quality (based on the MOS-HIV questionnaire)
6 Recruiting Incidence of Adverse Airway Events in High Risk Patients Undergoing Upper GI Endoscopy Under Anesthesia
Conditions: SEDLine;   Accoustic Respiratory Monitor RAD87;   Adverse Events;   Advanced Endoscopic Procedures
Intervention:
Outcome Measure: incidence of Adverse events
7 Unknown  Mechanisms of N-acetylcysteine Mediated Vascular Adverse Effects
Condition: Poisoning
Interventions: Drug: Chlorphenamine and Ranitidine;   Drug: Paracetamol
Outcome Measures: Attenuation of NAC induced vasodilatation by histamine antagonists (H1 and H2 antagonists) and/or paracetamol;   Inhibition of the inflammatory cascade contributes to a paracetamol mediated protective role against NAC Adverse reactions.
8 Recruiting Adverse Events During Upper Gastrointestinal Endoscopy
Conditions: Patients Need Upper Gastrointestinal Endoscopy;   Peptic Ulcer;   Gastric Cancer;   Esophagus Cancer;   Oesophagitis
Intervention:
Outcome Measure: Adverse events
9 Recruiting Study to Assess the Management of Synthetic Disease-modifying Antirheumatic Drug (DMARD) at the Onset of Adverse Events, Intolerance or Lack of Efficacy in Rheumatoid Arthritis (RA)
Condition: Rheumatoid Arthritis
Intervention:
Outcome Measures: Percentage of patients who present Adverse events, intolerance or lack of efficacy to synthetic DMARDs that causes a change in treatment prescription when used in routine clinical practice;   Percentage of patients who present Adverse events while on treatment with synthetic DMARDs and require a dose reduction of the synthetic DMARD in question;   percentage of patients who experience Adverse events while on treatment with synthetic DMARDs which forces drug withdrawal;   percentage of patients who require an alternative DMARD due to lack of efficacy, defined as primary or secondary failure according to the rheumatologist in-charge of treatment;   reasons for the different treatment strategies (discontinuation [temporary or permanent] versus dose reduction, failure due to lack of efficacy [primary or secondary] and the addition of other drugs) being adopted in the use of synthetic DMARDs.;   actual doses of the three first synthetic DMARDs used in clinical practice;   percentage of patients who receive subcutaneous methotrexate and the reasons for receiving it (improved efficacy, reduced toxicity, other or unknown);   exposure time of the first three synthetic DMARDs
10 Unknown  Adverse Reactions and Efficacy of Fixed-dose Combination Anti-tuberculosis (TB) Drugs
Condition: Tuberculosis
Intervention:
Outcome Measures: To compare the frequency of occurrence of Adverse reactions between using FDC and single drugs in pulmonary tuberculosis treatment;   To compare the efficacy of anti-TB treatment between using FDC and single drugs
11 Not yet recruiting The Effect of Probiotics on Response to Therapy and on Adverse Effect in Patients Treated With Colchicine for Familial Mediterranean Fever.
Condition: Familial Mediterranean Fever (FMF )
Interventions: Dietary Supplement: probiotic;   Dietary Supplement: Placebo
Outcome Measures: The number of gastrointestinal Adverse effect related to colchicine therapy after adding probiotics to colchicine therapy.;   Number of FMF attacks after adding the probiotics to the colchicine therapy
12 Recruiting Utility of PharmacoGenomics for Reducing Adverse Drug Effects
Condition: Genetics of Drug Metabolism
Intervention:
Outcome Measures: Occurrence of Meaningful Change in Drug Regimen;   Changes in target drug regimen over the 90-day period preceding receipt of PGx results, compared to the changes made in the 90-day period thereafter;   Number of Target Drug-Related Adverse events (TDAE) over the 90-day period preceding receipt of PGx test results compared with the number over the 90-day period after the test;   Target-drug related outpatient clinic visits, emergency department visits, and hospitalizations over the 90-day period prior to the receipt of PGx test results, compared to the number of visits over the 90-day period following testing.
13 Recruiting Adverse Events and Genomics in Schizophrenia
Condition: Adverse Effect of Other Antipsychotics and Neuroleptics
Interventions: Other: Blood samples for whole genomic/transcriptomic sequencing;   Other: UKU Side Effect Rating Scale
Outcome Measures: Concentration of whole-genome and/or transcriptome variants predicting weight gain, or glucose or lipid dysregulations in whole blood (ng/uL).;   Concentration of whole-genome and/or transcriptome variants predicting immune effects of clozapine monotherapy in whole blood (ng/uL).
14 Not yet recruiting ASIS for Botox in Upper Limb Spasticity
Conditions: Upper Limb Spasticity Unilaterally in Adults With History of Stroke;   Increased Muscle Tone in Elbow, Wrist, Finger, and Thumb Flexors.
Interventions: Drug: Gadolinium;   Drug: Efficacy of Botox intramuscularly at Week 6;   Drug: Efficacy of Botox intramuscularly at Week 12,;   Drug: Efficacy of Botox intramuscularly at Week 18;   Drug: Efficacy of Botox intramuscularly at Week 24;   Drug: Efficacy of Botox intramuscularly at Week 30;   Drug: Efficacy of Botox subdermally at Week 6;   Drug: Efficacy of Botox subdermally at Week 12;   Drug: Efficacy of Botox subdermally at Week 18;   Drug: Efficacy of Botox subdermally at Week 24;   Drug: Efficacy of Botox subdermally at Week 30;   Drug: Adverse Reactions of Botox intramuscularly;   Drug: Adverse Reactions of Botox subdermally
Outcome Measures: Relative Prolongation Ability Score for Gadolinium subdermally injected.;   Efficacy of Botox intramuscularly vs. subdermally in Upper Limb Spasticity.
15 Not yet recruiting ASIS for Botox in Chronic Migraine
Condition: Chronic Migraine More than15 Days Per Month, and Lasting 4 Hours a Day or Longer.
Interventions: Drug: Gadolinium;   Drug: Efficacy of Botox intramuscularly at Week 6;   Drug: Efficacy of Botox intramuscularly at Week 12;   Drug: Efficacy of Botox intramuscularly at Week 18;   Drug: Efficacy of Botox intramuscularly at Week 24,;   Drug: Efficacy of Botox intramuscularly at Week 30;   Drug: Efficacy of Botox subdermally at Week 6;   Drug: Efficacy of Botox subdermally at Week 12;   Drug: Efficacy of Botox subdermally at Week 18;   Drug: Efficacy of Botox subdermally at Week 24;   Drug: Efficacy of Botox subdermally at Week 30;   Drug: Adverse Reactions of Botox intramuscularly;   Drug: Adverse Reactions of Botox subdermally
Outcome Measures: Relative Prolongation Ability Score for Gadolinium subdermally injected.;   Efficacy of Botox intramuscularly vs. subdermally in Chronic Migraine.
16 Not yet recruiting ASIS for Botox in Cervical Dystonia
Conditions: Cervical Dystonia Adults ,;   Abnormal Head Position and Neck Pain for These 7 Muscle Groups: Splenius,Scalene,Sterno-cleido-mastoid,Levator Scapulae,Semispinalis,Trapezius,and Longissimus.
Interventions: Drug: Gadolinium;   Drug: Efficacy of Botox intramuscularly at Week 6;   Drug: Efficacy of Botox intramuscularly at Week 12;   Drug: Efficacy of Botox intramuscularly at Week 18;   Drug: Efficacy of Botox intramuscularly at Week 24;   Drug: Efficacy of Botox intramuscularly at Week 30;   Drug: Efficacy of Botox subdermally at Week 6;   Drug: Efficacy of Botox subdermally at Week 12;   Drug: Efficacy of Botox subdermally at Week 18;   Drug: Efficacy of Botox subdermally at Week 24;   Drug: Efficacy of Botox subdermally at Week 30;   Drug: Adverse Reactions of Botox intramuscularly;   Drug: Adverse Reactions of Botox subdermally
Outcome Measures: Relative Prolongation Ability Score for Gadolinium subdermally injected.;   Efficacy of Botox intramuscularly vs. subdermally in Cervical Dystonia.
17 Recruiting Observational Study to Assess the Incidence Rate of the Major Adverse Cardiovascular Events (MACE) and Safety of Fenofibrate (Lipilfen Capsule)
Condition: Metabolic Syndrome
Intervention: Other: Not applicable-observational study
Outcome Measures: The incidence rate of the major Adverse cardiovascular events (MACE);   The incidence rate of the major Adverse cardiac and cerebrovascular event (MACCE)
18 Not yet recruiting ASIS for Enbrel in Plaque Psoriasis
Condition: Plaque Psoriasis.
Interventions: Drug: Gadolinium;   Drug: Efficacy of Enbrel subcutaneously at Week 12;   Drug: Efficacy of Enbrel subcutaneously at Week 24;   Drug: Efficacy of Enbrel subcutaneously at Week 36;   Drug: Efficacy of Enbrel subdermally at Week 12;   Drug: Efficacy of Enbrel subdermally at Week 24;   Drug: Efficacy of Enbrel subdermally at Week 36;   Drug: PASI 75 n(%) subcutaneously at Week 12;   Drug: PASI 75 n(%) subcutaneously at Week 24;   Drug: PASI 75 n(%) subcutaneously at Week 36;   Drug: PASI 75 n(%) subdermally at Week 12;   Drug: PASI 75 n(%) subdermally at Week 24;   Drug: PASI 75 n(%) subdermally at Week 36;   Drug: Adverse Reactions of Enbrel subcutaneously;   Drug: Adverse Reactions of Enbrel subdermally at Week 36
Outcome Measures: Relative Prolongation Ability Score for Gadolinium subdermally injected.;   Efficacy of Enbrel subcutaneously vs. subdermally in Plaque Psoriasis.
19 Recruiting National Active Surveillance Network and Pharmacogenomics of Adverse Drug Reactions in Children
Condition: Adverse Drug Reaction (ADR)
Intervention:
Outcome Measure:
20 Recruiting Identification of Adverse Plaque Characteristics by Coronary MR Angiography
Condition: Coronary Artery Disease
Intervention: Other: Coronary MR Angiography (CMRA)
Outcome Measure: Adverse plaque characteristics present on CMRA

These studies may lead to new treatments and are adding insight into Adverse etiology and treatment.

A major focus of Adverse research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Adverse